Valentina Santo

Valentina Santo

Auto-generated profile, based on publicly available information

Valentina Santo

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
FPFederica Pecci
Federica Pecci
HLHui Li
Hui Li
Alessandro Di FedericoAlessandro Di Federico
Alessandro Di Federico
Jia WuJia Wu
Jia Wu
HCHong Chen
Hong Chen
XLXiuning Le
Xiuning Le
Purpose: First-line treatment options for MET exon 14 skipping–mutant metastatic non–small cell lung cancer vary because of differences in drug approvals and clinical experience. This study investigates factors influencing outcomes with first-line MET tyrosine kinase inhibitors (TKI) versus immune checkpoint inhibitors (ICI) ± chemotherapy. Experimental Design: Clinicopathologic data were collected from patients with metastatic MET exon 14 skipping–mutant non–small cell lung cancer treated with first-line MET TKI or ICI ± chemotherapy at five centers. Primary endpoints were real-world progression-free survival (rwPFS) and overall survival (OS) to first-line MET TKI versus ICI ± chemotherapy. Subgroup analyses by clinical and tumor characteristics were performed. Results: Among 158 patients, 80 received MET TKI and 78 received ICI ± chemotherapy as first-line treatment. Baseline clinicopathologic features were balanced except for a higher proportion of patients with a history of smoking in the ICI ± chemotherapy group (P = 0.03). With a median follow-up of 37.9 months, no difference was observed in rwPFS (HR, 0.85; P = 0.4) or OS (HR, 0.97; P = 0.9) with first-line MET TKI versus ICI ± chemotherapy. In subgroup analyses, first-line ICI ± chemotherapy improved rwPFS in PD-L1 ≥80% (HR, 0.50; P = 0.03), whereas MET TKI improved rwPFS (HR, 0.40; P = 0.005) and OS (HR, 0.49; P = 0.03) in PD-L1 <50%, as well as rwPFS (HR, 0.39; P = 0.02) and OS (HR, 0.36; P = 0.03) in brain metastases and rwPFS (HR, 0.55; P = 0.01) in bone metastases. No significant differences were observed in the incidence of high-grade toxicity (P = 0.9) or rates of permanent treatment discontinuation (P = 0.2) between first-line MET TKI and ICI ± chemotherapy. Conclusions: First-line MET TKI improved outcomes in PD-L1 <50% and brain/bone metastases, whereas ICI ± chemotherapy prolonged PFS only in PD-L1 ≥80%, emphasizing the need for personalized treatment selection.

18 April 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
FPFederica Pecci
Federica Pecci
RTRohit Thummalapalli
Rohit Thummalapalli
SAStephanie L. Alden
Stephanie L. Alden
BRBiagio Ricciuti
Biagio Ricciuti
JAJoao V. Alessi
Joao V. Alessi
MAMark M. Awad
Mark M. Awad
Purpose: Among patients with advanced non–small cell lung cancer (NSCLC) who discontinue immune checkpoint inhibitors (ICI) because of immune-related adverse events (irAE), post-discontinuation clinical outcomes and factors associated with disease progression after discontinuation are largely unknown. Experimental Design: Clinicopathologic data were abstracted from patients with advanced NSCLC who received ICI and discontinued treatment because of irAE. Factors associated with post-discontinuation progression-free survival (PFS) and post-discontinuation overall survival (OS) were evaluated. Results: Of 2,794 patients, 10% (N = 271) discontinued ICI because of irAE, and the median duration of ICI treatment before discontinuation for irAE was 5.9 months (range, 0.03–73.5). A longer treatment duration before discontinuation for irAE was associated with improved post-discontinuation outcomes: for patients on ICI for 6 months (N = 133) before discontinuing for irAE, the median post-discontinuation PFS was 6.2, 13.9, and 25.8 months (P < 0.001), respectively, and the median post-discontinuation OS was 21.7, 42.7, and 86.9 months (P < 0.001), respectively. At multivariable analyses, predictors of longer post-discontinuation PFS were PD-L1 ≥ 50%, complete response/partial response (CR/PR) to treatment, and treatment duration before discontinuation between 3 to 6 months and >6 months; predictors of longer post-discontinuation OS were nonsquamous histology, CR/PR, and treatment duration before discontinuation >6 months. The use of immunosuppressive agents for toxicity management did not affect post-discontinuation outcomes. Conclusions: A longer treatment duration before discontinuation, a best objective response of CR/PR, PD-L1 ≥50%, and nonsquamous histology may help clinicians identify patients who may experience long-term disease control after discontinuation of ICI for irAE.

1 June 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
EGEleonora Gariazzo
Eleonora Gariazzo
SLSanna Laaksonen
Sanna Laaksonen
SCStephanie Canty
Stephanie Canty
GAGuilherme Rossato De Almeida
Guilherme Rossato De Almeida
IOIgor Odintsov
Igor Odintsov
BRBiagio Ricciuti
Biagio Ricciuti

1 July 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CFCassio Murilo Trovo Hidalgo Filho
Cassio Murilo Trovo Hidalgo Filho
VSValentina Santo
Valentina Santo
EGEleonora Gariazzo
Eleonora Gariazzo
MAMihaela Aldea
Mihaela Aldea
FPFederica Pecci
Federica Pecci
BRBiagio Ricciuti
Biagio Ricciuti
Acquired resistance (AR) to immune checkpoint inhibitors (ICIs) remains a major obstacle to durable clinical benefit in non–small cell lung cancer (NSCLC). Emerging after initial responses, AR reflects tumor evolution, immune escape, and metabolic reprogramming. Key mechanisms may include impaired antigen presentation (β2-microglobulin, human leukocyte antigen mutations), T-cell exhaustion, and remodeling of the tumor microenvironment (TME). In this review, we summarize the current understanding of ICIs resistance and highlight therapeutic strategies under investigation to overcome it. Novel approaches include next-generation ICIs targeting TIGIT and LAG-3, epigenetic modulators (HDAC, DNMT inhibitors), and metabolic agents relevant to STK11 and KEAP1 mutations. Additional strategies aim to reprogram the TME through AXL or multikinase inhibition, tumor-treating fields, and cytokine- and/or gene-based therapies. Cellular immunotherapies (tumor-infiltrating lymphocytes, T-cell receptors, chimeric antigen receptor-T), antibody-drug conjugates, and vaccines offer complementary means to restore antitumor immunity. Advancing the field will require biomarker-driven patient selection and rational combinations to overcome AR and achieve more durable, personalized immunotherapy outcomes in NSCLC.

16 October 2025 in Lung Cancer
Verified
Journal Article
Open access
ACAlessio Cortellini
Alessio Cortellini
Edoardo GarboEdoardo Garbo
Edoardo Garbo
GCGiulia La Cava
Giulia La Cava
FCFabrizio Citarella
Fabrizio Citarella
VSValentina Santo
Valentina Santo
VGValerio Guarrasi
Valerio Guarrasi
The use of first-line single agent immunotherapy in patients with advanced NSCLC and ECOG PS ≥ 2 remains controversial, as this frail population has been largely excluded from pivotal clinical trials. Real-world evidence suggests that although median survival is poor, a subset of these patients may achieve long-term benefit. We analyzed data from the Pembro-Real 5Y registry, a global real-world dataset with > 5 years follow-up. The cohort included patients with advanced NSCLC, PD-L1 TPS ≥ 50 %, treated with first line pembrolizumab outside of clinical trials. Univariable analyses were conducted to identify descriptive characteristics associated with survival. To address the complexity of long-term outcome prediction, we integrated Elastic Net regression and a transformer-based AI model (NAIM). The Elastic Net model was employed to mitigate collinearity and select relevant prognostic factors, while NAIM was used to explore non-linear, time-dependent interactions between variables. Endpoints included overall survival (OS) and 5-year survival rates. Out of 1050 patients, 161 patients with ECOG PS ≥ 2 were included, showing a median OS of 5.4 months (95 % CI: 3.8-7.8), and a 5-year survival rate of 13.0 % (95 % CI: 8.1-19.9). Univariable analysis indicated that no single baseline variable was strongly predictive of 5-year survival, except for TMB, KRAS, and BRAF status, which were significantly limited by missingness. Elastic Net identified only two significant predictors of 5-year survival: high TMB (with unstable confidence intervals) and KRAS mutation. NAIM provided a dynamic perspective, confirming that bone metastases and baseline corticosteroid use were strong predictors of early mortality, whereas BMI increase and systemic health markers/host factors (e.g., hypertension and dyslipidemia) gained importance in long-term survivors. However, NAIM exhibited a notable performance drop from training to validation suggesting overfitting and the challenge of modeling long-term outcomes using baseline static variables. Despite the overall poor prognosis, a subset of patients with ECOG PS ≥ 2 achieves long-term survival with pembrolizumab monotherapy, indicating that performance status alone should not preclude treatment in all cases. Our analysis highlights the limitations of traditional statistical approaches and AI-driven models in predicting long-term benefit in this heterogeneous population. Future efforts should focus on refining hybrid modeling strategies and incorporating prospective validation to better identify those who may benefit from immunotherapy beyond short-term expectations.